NeurogesX to Report Third Quarter 2008 Financial Results


    SAN MATEO, Calif., Oct. 29 /CNW/ -- NeurogesX, Inc. (Nasdaq:   NGSX), a
biopharmaceutical company focused on developing and commercializing novel pain
management therapies, today announced it will report results for its third
quarter 2008  on Thursday, November 6, 2008, after the market closes.

    A conference call to review the results and discuss corporate and
clinical initiatives for the remainder of 2008 and into 2009 will begin at
4:30 p.m. ET (1:30 p.m. PT) on November 6, 2008 and will be hosted by Anthony
DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief
Financial Officer.

    To participate in the conference call, please dial 1-877-407-0789 (USA)
or 1-201-689-8562 (International). In addition, a dial-up replay of the
conference call will be available beginning November 6, 2008 at 8:00 p.m. ET
(5:00 p.m. PT) and ending on November 16, 2008. The replay telephone number is
1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055,
Conference ID Number: 301804.

    A live web cast of the call will also be available from the Investor
Relations section on the corporate web site at A web
cast replay can be accessed on the corporate web site beginning November 6,
2008 at the same time as the conference call and will remain on the site for
one month ending December 6, 2008.

    About NeurogesX, Inc.

    NeurogesX (Nasdaq:   NGSX) is a biopharmaceutical company focused on
developing and commercializing novel pain management therapies. Its initial
focus is on chronic peripheral neuropathic pain, including postherpetic
neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and
painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is
led by its product candidate NGX-4010, a dermal patch designed to manage pain
associated with peripheral neuropathic pain conditions, that the Company
believes offers significant advantages over other pain therapies. NeurogesX
submitted a new drug application (NDA) for NGX-4010 with the U.S. Food and
Drug Administration (FDA) in October 2008 for PHN, which is subject to
acceptance by the FDA. Additionally, a marketing authorization application
(MAA) for NGX-4010 seeking approval for peripheral neuropathic pain is
currently under review by the European Medicines Agency (EMEA). NeurogesX'
second most advanced product candidate, NGX-1998, is a topically applied,
liquid formulation containing a high concentration of capsaicin designed to
treat pain associated with neuropathic pain conditions. NGX-1998 is currently
in a Phase 1 clinical trial.  The objective of the development program for
NGX-1998 is to determine its ability to provide protracted pain relief from a
single treatment.  As a liquid, NGX-1998 is expected to be suitable for areas
of the skin where dermal patches may be difficult or impractical to apply,
such as the hairline.  NGX-1998 is being developed with the goal of it
becoming a product that has the potential to be used by a broad spectrum of
the physician population.  NGX-1998 was previously studied in two Phase 1
studies in healthy volunteers conducted under an exploratory investigational
new drug application.

    Safe Harbor Statement
    This press release contains forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX
disclaims any intent or obligation to update these forward-looking statements,
and claims the protection of the Safe Harbor for forward-looking statements
contained in the Act. Examples of such statements include, but are not limited
to,  possible approval of NeurogesX' product candidates by the FDA or EMEA,
the potential markets for NeurogesX' product candidates and the expected
benefits of NeurogesX' product candidates; the suitability of NGX-1998 for
certain treatments and potential usage by broader physician populations. Such
statements are based on management's current expectations, but actual results
may differ materially due to various risks and uncertainties, including, but
not limited to, NeurogesX' product candidates may have unexpected adverse side
effects or inadequate therapeutic efficacy; positive results in clinical
trials may not be sufficient to obtain FDA or European regulatory approval;
any regulatory approvals which are received may be limited to certain
indications; physician or patient reluctance to use NGX-4010 or NGX-1998, if
approved, or the inability of physicians to obtain sufficient reimbursement
for such procedures; potential alternative therapies; maintaining adequate
patent or trade secret protection without violating the intellectual property
rights of others; and other difficulties or delays in, clinical development,
obtaining regulatory approval, market acceptance and commercialization of
NeurogesX' product candidates and the advantages of NeurogesX' product
candidates over other pain therapies. For further information regarding these
and other risks related to NeurogesX' business, investors should consult
NeurogesX' filings with the Securities and Exchange Commission.


    NeurogesX, Inc.
    Stephen Ghiglieri
    Chief Financial Officer
    (650) 358-3310

    The Ruth Group
    Stephanie Carrington / Sara Ephraim (investors)
    (646) 536-7017 / 7002

    Jason Rando (media)
    (646) 536-7025


For further information:

For further information: Stephen Ghiglieri, +1-650-358-3310, Chief
Financial Officer of NeurogesX, Inc.; Investors, Stephanie Carrington, or Sara
Ephraim, +1-646-536-7017, +1-646-536-7002,,, both of The Ruth Group for NeurogesX, Inc.; Media,
Jason Rando, +1-646-536-7025,, for NeurogesX, Inc.

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890